Objective: Caffeine (Caf) counteracts various effects of benzodiazepines (B
ZDs). Since the effects of zolpidem, a short-acting atypical GABAA-BZD agon
ist, were not antagonized by Caf, we studied am interaction between Caf;and
midazolam (Mid) in healthy volunteers. Subjects, materials and methods: In
Study 1, 108 healthy students divided to 6 parallel groups were given Mid
12 mg (capsule) and Caf 125 and 250 mg (in decaffeinated coffee), alone and
in combinations in the double-blind placebo-controlled manner. Objective a
nd subjective tests were done before and at 45 and 90 min after intake. Ran
ked Delta -values (changes from base:line) were analyzed by one-way contras
t ANOVA and Scheffe's tests. In Study 2, six healthy subjects took Mid 15 m
g (tablet) with and without Caf 300 mg. The dynamic effects were analyzed a
s in Study 1 and the plasma concentrations were assayed. Results: Study 1,
learn effects after placebo (ad +15%) were seen for letter cancellation and
digit symbol substitution tests. Midazolam alone significantly (p < 0.05 v
s. <Delta>-placebo) reduced letter cancellation and digit symbol substituti
on, lowered flicker fusion, impaired digit learning and caused subjective c
almness on VAS. Caffeine alone did not differ from placebo objectively, yet
improved quick-wittedness and contentedness on VAS. In the combinations, M
id+Caf 125 mg differed from placebo objectively as Mid alone, whereas Mid Caf 250 mg did not. Mid + Caf 250 mg differed from Mid on digit substituti
on, but did not differ from Mid+Caf 150 mg in impairing memory and causing
subjective sedation. In Study 2, Mid 15 mg caused sedation and Caf300 mg in
creased plasma Mid at 45 min. Mid + Caf did not differ from Mid alone objec
tively, but did so subjectively on VAS (p > 0.05). Conclusion: In conclusio
n, in a parallel group study, sedative effects of Mid 12 mg were only moder
ately antagonized by Caf 250 mg but not by Caf 125 mg. In a crossover study
, a weak interaction was found subjectively but not in objective measures.